Urvashi Soni

Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by symptoms of hyperactivity, inattention, and impulsivity, significantly impacting individuals' daily functioning and quality of life. This manuscript explores the intricate relationship between the gut microbiome and ADHD, emphasizing the role of the gut-brain axis, a bidirectional communication pathway linking the central nervous system (CNS) and the gastrointestinal tract (GIT). The composition of gut microbiota influences several physiological processes, including immune function, metabolism, and the production of neuroactive metabolites, which are critical for cognitive functions such as memory and decision-making. The review discusses alternative therapeutic options, including dietary modifications, synbiotics, and specific diets like the ketogenic diet, which may offer promising outcomes in managing ADHD symptoms. Further research is necessary to establish the efficacy and mechanisms of action of synbiotics and dietary interventions, despite preliminary studies suggesting their potential benefits. This review article aims to provide a comprehensive overview of the current understanding of the gut microbiome's impact on ADHD, highlighting the need for continued investigation into innovative treatment strategies that leverage the gut-brain connection.

: In recent years, the use of natural compounds derived from plants for the treatment of skin cancer has gained significant attention due to their potential therapeutic effects and minimal side effects. This review focuses on the innovative approach of utilizing biocomponents sourced from plants in combination with backpropagation neural networks (BPNN) for the screening and analysis of skin cancer treatments. The integration of plant-derived compounds and AI-driven algorithms holds promise for enhancing the precision and effectiveness of skin cancer therapies. The review begins by highlighting the escalating global burden of skin cancer and the limitations of conventional treatment approaches. With the rise in concerns about the adverse effects of synthetic drugs, researchers have turned their attention towards exploring the therapeutic potential of plant-derived biocomponents. These natural compounds are known for their rich bioactive constituents that exhibit anti-cancer properties, making them suitable candidates for skin cancer treatment. One of the key challenges in harnessing the potential of plant-derived compounds is the need for accurate screening and analysis of their effects. This is where backpropagation neural networks, a type of artificial neural network, comes into play. These networks can process complex data and recognize intricate patterns, enabling them to predict the efficacy of various biocomponents in combating skin cancer. The review delves into the functioning of BPNN and its applications in drug discovery and treatment evaluation. Furthermore, the review explores several case studies that demonstrate the successful integration of plant-derived compounds with BPNN in the context of skin cancer treatment. These studies provide evidence of how this synergistic approach can lead to improved treatment outcomes by minimizing adverse effects and maximizing therapeutic benefits. The methodology section discusses the steps involved in training the neural network using relevant datasets and optimizing its performance for accurate predictions. While the integration of plant-derived compounds and BPNN shows great promise, the review also addresses the existing challenges and limitations. These include the need for comprehensive and standardized datasets, potential biases in training data, and the complexity of neural network architectures. The regulatory considerations surrounding plant-based therapies are also discussed, highlighting the importance of rigorous testing and validation.

: Neurodegenerative disorders, which include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), represent a significant and growing global health challenge. Current therapies predominantly focus on symptom management rather than altering disease progression. In this review, we discuss the major therapeutic strategies in practice for these disorders, highlighting their limitations. For AD, the mainstay treatments are cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. For PD, dopamine replacement therapies, including levodopa, are commonly used. HD is managed primarily with symptomatic treatments, and reusable extends survival in ALS. However, none of these therapies halts or substantially slows the neurodegenerative process. In contrast, this review highlights emerging research into bioactive peptides as potential therapeutic agents. These naturally occurring or synthetically designed molecules can interact with specific cellular targets, potentially modulating disease processes. Preclinical studies suggest that bioactive peptides may mitigate oxidative stress, inflammation, and protein misfolding, which are common pathological features in neurodegenerative diseases. Clinical trials using bioactive peptides for neurodegeneration are limited but show promising initial results. For instance, hemiacetal, a γ-secretase inhibitor peptide, has shown potential in AD by reducing amyloid-beta production, though its development was discontinued due to side effects. Despite these advancements, many challenges remain, including identifying optimal peptides, confirming their mechanisms of action, and overcoming obstacles related to their delivery to the brain. Future research should prioritize the discovery and development of novel bioactive peptides and improve our understanding of their pharmacokinetics and pharmacodynamics. Ultimately, this approach may lead to more effective therapies for neurodegenerative disorders, moving beyond symptom management to potentially modify the course of these devastating diseases.